These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21333635)

  • 1. Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition.
    Möhler H; Boison D; Singer P; Feldon J; Pauly-Evers M; Yee BK
    Biochem Pharmacol; 2011 May; 81(9):1065-77. PubMed ID: 21333635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1.
    Singer P; Yee BK; Feldon J; Iwasato T; Itohara S; Grampp T; Prenosil G; Benke D; Möhler H; Boison D
    Neuroscience; 2009 Jun; 161(2):635-54. PubMed ID: 19332109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents.
    Deiana S; Hauber W; Munster A; Sommer S; Ferger B; Marti A; Schmid B; Dorner-Ciossek C; Rosenbrock H
    Eur J Pharmacol; 2022 Nov; 935():175306. PubMed ID: 36183855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
    Chaki S; Shimazaki T; Karasawa J; Aoki T; Kaku A; Iijima M; Kambe D; Yamamoto S; Kawakita Y; Shibata T; Abe K; Okubo T; Sekiguchi Y; Okuyama S
    Psychopharmacology (Berl); 2015 Aug; 232(15):2849-61. PubMed ID: 25869273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).
    Chue P
    Curr Pharm Des; 2013; 19(7):1311-20. PubMed ID: 23194655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia.
    Pei JC; Luo DZ; Gau SS; Chang CY; Lai WS
    Front Psychiatry; 2021; 12():742058. PubMed ID: 34658976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
    Harada K; Nakato K; Yarimizu J; Yamazaki M; Morita M; Takahashi S; Aota M; Saita K; Doihara H; Sato Y; Yamaji T; Ni K; Matsuoka N
    Eur J Pharmacol; 2012 Jun; 685(1-3):59-69. PubMed ID: 22542656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intact working memory in the absence of forebrain neuronal glycine transporter 1.
    Dubroqua S; Serrano L; Boison D; Feldon J; Gargiulo PA; Yee BK
    Behav Brain Res; 2012 Apr; 230(1):208-14. PubMed ID: 22342492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.
    Yee BK; Balic E; Singer P; Schwerdel C; Grampp T; Gabernet L; Knuesel I; Benke D; Feldon J; Mohler H; Boison D
    J Neurosci; 2006 Mar; 26(12):3169-81. PubMed ID: 16554468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?
    Singer P; Boison D; Möhler H; Feldon J; Yee BK
    Behav Neurosci; 2009 Oct; 123(5):1012-27. PubMed ID: 19824767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
    Surti TS; Ranganathan M; Johannesen JK; Gueorguieva R; Deaso E; Kenney JG; Krystal JH; D'Souza DC
    Schizophr Res; 2023 Jun; 256():36-43. PubMed ID: 37141764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
    Pei JC; Hung WL; Lin BX; Shih MH; Lu LY; Luo DZ; Tai HC; Studer V; Min MY; Lai WS
    J Psychopharmacol; 2019 Oct; 33(10):1288-1302. PubMed ID: 31294644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia.
    Rosenbrock H; Dorner-Ciossek C; Giovannini R; Schmid B; Schuelert N
    J Pharmacol Exp Ther; 2022 Aug; 382(2):223-232. PubMed ID: 35661632
    [No Abstract]   [Full Text] [Related]  

  • 15. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
    Bridges TM; Williams R; Lindsley CW
    Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.
    D'Souza DC; Carson RE; Driesen N; Johannesen J; Ranganathan M; Krystal JH;
    Biol Psychiatry; 2018 Sep; 84(6):413-421. PubMed ID: 29499855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine transporter 1 is a target for the treatment of epilepsy.
    Shen HY; van Vliet EA; Bright KA; Hanthorn M; Lytle NK; Gorter J; Aronica E; Boison D
    Neuropharmacology; 2015 Dec; 99():554-65. PubMed ID: 26302655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential.
    Alberati D; Moreau JL; Mory R; Pinard E; Wettstein JG
    Pharmacol Biochem Behav; 2010 Dec; 97(2):185-91. PubMed ID: 20678516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
    Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
    Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.